{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T07:11:46Z","timestamp":1770966706109,"version":"3.50.1"},"reference-count":75,"publisher":"National Institute for Health and Care Research","issue":"44","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["16\/95\/01"],"award-info":[{"award-number":["16\/95\/01"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background<\/jats:title>\n Sexual dysfunction is common among people who are prescribed antipsychotic medication for psychosis. Sexual dysfunction can impair quality of life and reduce treatment adherence. Switching antipsychotic medication may help, but the clinical effectiveness and cost-effectiveness of this approach is unclear.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To examine whether or not switching antipsychotic medication provides a clinically effective and cost-effective method to reduce sexual dysfunction in people with psychosis.<\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n A two-arm, researcher-blind, pilot randomised trial with a parallel qualitative study and an internal pilot phase. Study participants were randomised to enhanced standard care plus a switch of antipsychotic medication or enhanced standard care alone in a 1\u2009:\u20091 ratio. Randomisation was via an independent and remote web-based service using dynamic adaptive allocation, stratified by age, gender, Trust and relationship status.<\/jats:p>\n <\/jats:sec>\n \n Setting<\/jats:title>\n NHS secondary care mental health services in England.<\/jats:p>\n <\/jats:sec>\n \n Participants<\/jats:title>\n Potential participants had to be aged \u2265\u200918 years, have schizophrenia or related psychoses and experience sexual dysfunction associated with the use of antipsychotic medication. We recruited only people for whom reduction in medication dosage was ineffective or inappropriate. We excluded those who were acutely unwell, had had a change in antipsychotic medication in the last 6 weeks, were currently prescribed clozapine or whose sexual dysfunction was believed to be due to a coexisting physical or mental disorder.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Switching to an equivalent dose of one of three antipsychotic medications that are considered to have a relatively low propensity for sexual side effects (i.e. quetiapine, aripiprazole or olanzapine). All participants were offered brief psychoeducation and support to discuss their sexual health and functioning.<\/jats:p>\n <\/jats:sec>\n \n Main outcome measures<\/jats:title>\n The primary outcome was patient-reported sexual dysfunction, measured using the Arizona Sexual Experience Scale. Secondary outcomes were researcher-rated sexual functioning, mental health, side effects of medication, health-related quality of life and service utilisation. Outcomes were assessed 3 and 6 months after randomisation. Qualitative data were collected from a purposive sample of patients and clinicians to explore barriers to recruitment.<\/jats:p>\n <\/jats:sec>\n \n Sample size<\/jats:title>\n Allowing for a 20% loss to follow-up, we needed to recruit 216 participants to have 90% power to detect a 3-point difference in total Arizona Sexual Experience Scale score (standard deviation 6.0 points) using a 0.05 significance level.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The internal pilot was discontinued after 12 months because of low recruitment. Ninety-eight patients were referred to the study between 1 July 2018 and 30 June 2019, of whom 10 were randomised. Eight (80%) participants were followed up 3 months later. Barriers to referral and recruitment included staff apprehensions about discussing side effects, reluctance among patients to switch medication and reticence of both staff and patients to talk about sex.<\/jats:p>\n <\/jats:sec>\n \n Limitations<\/jats:title>\n Insufficient numbers of participants were recruited to examine the study hypotheses.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n It may not be possible to conduct a successful randomised trial of switching antipsychotic medication for sexual functioning in people with psychosis in the NHS at this time.<\/jats:p>\n <\/jats:sec>\n \n Future work<\/jats:title>\n Research examining the acceptability and effectiveness of adjuvant phosphodiesterase inhibitors should be considered.<\/jats:p>\n <\/jats:sec>\n \n Trial registration<\/jats:title>\n Current Controlled Trials ISRCTN12307891.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment<\/jats:italic>; Vol. 24, No. 44. See the NIHR Journals Library website for further project information.<\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/hta24440","type":"journal-article","created":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T15:13:58Z","timestamp":1600096438000},"page":"1-54","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Switching antipsychotic medication to reduce sexual dysfunction in people with psychosis: the REMEDY RCT"],"prefix":"10.3310","volume":"24","clinical-trial-number":[{"clinical-trial-number":"isrctn12307891","registry":"10.18810\/isrctn","type":"results"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3137-5772","authenticated-orcid":true,"given":"Michael J","family":"Crawford","sequence":"first","affiliation":[{"name":"Division of Psychiatry, Imperial College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8343-5549","authenticated-orcid":true,"given":"Lavanya","family":"Thana","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, Imperial College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0960-9843","authenticated-orcid":true,"given":"Rachel","family":"Evans","sequence":"additional","affiliation":[{"name":"North Wales Organisation for Randomised Trials in Health and Social Care, University of Bangor, Bangor, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7526-8077","authenticated-orcid":true,"given":"Alexandra","family":"Carne","sequence":"additional","affiliation":[{"name":"Tees, Esk and Wear Valleys NHS Foundation Trust, Darlington, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4580-0840","authenticated-orcid":true,"given":"Lesley","family":"O\u2019Connell","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, Imperial College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5041-4621","authenticated-orcid":true,"given":"Amy","family":"Claringbold","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, Imperial College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8924-724X","authenticated-orcid":true,"given":"Arunan","family":"Saravanamuthu","sequence":"additional","affiliation":[{"name":"Central and North West London NHS Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4080-4807","authenticated-orcid":true,"given":"Rebecca","family":"Case","sequence":"additional","affiliation":[{"name":"Central and North West London NHS Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2368-9464","authenticated-orcid":true,"given":"Jasna","family":"Munjiza","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, Imperial College London, London, UK"},{"name":"Central and North West London NHS Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5028-3465","authenticated-orcid":true,"given":"Sandra","family":"Jayacodi","sequence":"additional","affiliation":[{"name":"Central and North West London NHS Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2469-9878","authenticated-orcid":true,"given":"Joseph G","family":"Reilly","sequence":"additional","affiliation":[{"name":"Tees, Esk and Wear Valleys NHS Foundation Trust, Darlington, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4480-0806","authenticated-orcid":true,"given":"Elizabeth","family":"Hughes","sequence":"additional","affiliation":[{"name":"School of Healthcare, University of Leeds, Leeds, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1803-5482","authenticated-orcid":true,"given":"Zoe","family":"Hoare","sequence":"additional","affiliation":[{"name":"North Wales Organisation for Randomised Trials in Health and Social Care, University of Bangor, Bangor, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0270-6256","authenticated-orcid":true,"given":"Barbara","family":"Barrett","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry, Psychology and Neuroscience, King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7548-8096","authenticated-orcid":true,"given":"Verity C","family":"Leeson","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, Imperial College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7756-1031","authenticated-orcid":true,"given":"Carol","family":"Paton","sequence":"additional","affiliation":[{"name":"Oxleas NHS Foundation Trust, Kent, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4727-5880","authenticated-orcid":true,"given":"Patrick","family":"Keown","sequence":"additional","affiliation":[{"name":"Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6303-1547","authenticated-orcid":true,"given":"Sofia","family":"Pappa","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, Imperial College London, London, UK"},{"name":"West London NHS Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1781-3070","authenticated-orcid":true,"given":"Charlotte","family":"Green","sequence":"additional","affiliation":[{"name":"Central and North West London NHS Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2324-656X","authenticated-orcid":true,"given":"Thomas RE","family":"Barnes","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, Imperial College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6221","published-online":{"date-parts":[[2020,9]]},"reference":[{"key":"key20200910144218905_ref1-bib1","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1093\/schbul\/sbl071","article-title":"Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis","volume":"33","author":"Eack","year":"2007","journal-title":"Schizophr Bull"},{"key":"key20200910144218905_ref1-bib2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/YIC.0b013e32836508e6","article-title":"The social and economic burden of treatment-resistant schizophrenia: a systematic literature review","volume":"29","author":"Kennedy","year":"2014","journal-title":"Int Clin Psychopharmacol"},{"key":"key20200910144218905_ref1-bib3","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1177\/0269881110391123","article-title":"Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology","volume":"25","author":"Barnes","year":"2011","journal-title":"J Psychopharmacol"},{"key":"key20200910144218905_ref1-bib4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3109\/15622975.2012.739708","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects","volume":"14","author":"Hasan","year":"2013","journal-title":"World J Biol Psychiatry"},{"key":"key20200910144218905_ref1-bib5","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1016\/j.jsxm.2019.08.022","article-title":"Management of antipsychotic-related sexual dysfunction: systematic review","volume":"16","author":"Allen","year":"2019","journal-title":"J Sex Med"},{"key":"key20200910144218905_ref1-bib6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1192\/bjp.182.1.50","article-title":"Nithsdale Schizophrenia Surveys 24: sexual dysfunction. Case\u2013control study","volume":"182","author":"Macdonald","year":"2003","journal-title":"Br J Psychiatry"},{"key":"key20200910144218905_ref1-bib7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1192\/bjp.181.1.49","article-title":"Sexual dysfunction in patients taking conventional antipsychotic medication","volume":"181","author":"Smith","year":"2002","journal-title":"Br J Psychiatry"},{"key":"key20200910144218905_ref1-bib8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/0269881114562090","article-title":"\u2018First do no harm.\u2019 A systematic review of the prevalence and management of antipsychotic adverse effects","volume":"29","author":"Young","year":"2015","journal-title":"J Psychopharmacol"},{"key":"key20200910144218905_ref1-bib9","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1192\/apt.9.3.202","article-title":"Sexual side-effects of antidepressant and antipsychotic drugs","volume":"9","author":"Baldwin","year":"2003","journal-title":"Adv Psychiatr Treat"},{"key":"key20200910144218905_ref1-bib10","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/schbul\/sbv001","article-title":"The facts about sexual (Dys)function in schizophrenia: an overview of clinically relevant findings","volume":"41","author":"de Boer","year":"2015","journal-title":"Schizophr Bull"},{"key":"key20200910144218905_ref1-bib11","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs"},{"key":"key20200910144218905_ref1-bib12","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00345-006-0136-5","article-title":"Adverse effects of drug therapies on male and female sexual function","volume":"24","author":"Stadler","year":"2006","journal-title":"World J Urol"},{"key":"key20200910144218905_ref1-bib13","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1001\/jama.281.6.537","article-title":"Sexual dysfunction in the United States: prevalence and predictors","volume":"281","author":"Laumann","year":"1999","journal-title":"JAMA"},{"key":"key20200910144218905_ref1-bib14","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/j.1743-6109.2005.00173.x","article-title":"Moderate and severe erectile dysfunction equally affects life satisfaction","volume":"3","author":"Mallis","year":"2006","journal-title":"J Sex Med"},{"key":"key20200910144218905_ref1-bib15","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.psychres.2014.02.009","article-title":"Low satisfaction with sex life among people with severe mental illness living in a community","volume":"216","author":"Ostman","year":"2014","journal-title":"Psychiatry Res"},{"key":"key20200910144218905_ref1-bib16","doi-asserted-by":"publisher","first-page":"331","DOI":"10.4088\/jcp.v66n0309","article-title":"Male sexual dysfunction and quality of life in schizophrenia","volume":"66","author":"Olfson","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"key20200910144218905_ref1-bib17","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/00926230390195524","article-title":"A survey of sexual side effects among severely mentally ill patients taking psychotropic medications: impact on compliance","volume":"29","author":"Rosenberg","year":"2003","journal-title":"J Sex Marital Ther"},{"key":"key20200910144218905_ref1-bib18","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1017\/s0033291700036539","article-title":"Subjective utility ratings of neuroleptics in treating schizophrenia","volume":"20","author":"Finn","year":"1990","journal-title":"Psychol Med"},{"key":"key20200910144218905_ref1-bib19","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1192\/pb.21.2.99","article-title":"\u2018No sex please we\u2019re British\u2019 \u2013 taking a sexual history from in-patients","volume":"21","author":"Singh","year":"1997","journal-title":"Psychiatr Bull"},{"key":"key20200910144218905_ref1-bib20","unstructured":"Barnes T, Paton C. The Prescribing Observatory for Mental Health 10-Year Report: Supporting Rational, Effective and Safe Prescribing in Mental Health Services. London: Royal College of Psychiatrists; 2016."},{"key":"key20200910144218905_ref1-bib21","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1192\/pb.22.6.365","article-title":"How do psychiatric out patients feel about the sexual history?","volume":"22","author":"Crawford","year":"1998","journal-title":"Psychiatr Bull"},{"key":"key20200910144218905_ref1-bib22","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1186\/s12888-016-1103-3","article-title":"Prolactin related symptoms during risperidone maintenance treatment: results from a prospective, multicenter study of schizophrenia","volume":"16","author":"Bo","year":"2016","journal-title":"BMC Psychiatry"},{"key":"key20200910144218905_ref1-bib23","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1177\/0269881107082901","article-title":"Change in sexual dysfunction with aripiprazole: a switching or add-on study","volume":"22","author":"Mir","year":"2008","journal-title":"J Psychopharmacol"},{"key":"key20200910144218905_ref1-bib24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1080\/00926230490465082","article-title":"An open-label trial of quetiapine for antipsychotic-induced sexual dysfunction","volume":"30","author":"Byerly","year":"2004","journal-title":"J Sex Marital Ther"},{"key":"key20200910144218905_ref1-bib25","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.psyneuen.2005.12.006","article-title":"Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine","volume":"31","author":"Kinon","year":"2006","journal-title":"Psychoneuroendocrinology"},{"key":"key20200910144218905_ref1-bib26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.psychres.2007.02.014","article-title":"Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial","volume":"159","author":"Byerly","year":"2008","journal-title":"Psychiatry Res"},{"key":"key20200910144218905_ref1-bib27","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1176\/ajp.2006.163.12.2090","article-title":"Effectiveness of switching antipsychotic medications","volume":"163","author":"Essock","year":"2006","journal-title":"Am J Psychiatry"},{"key":"key20200910144218905_ref1-bib28","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1471-244X-9-54","article-title":"Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia","volume":"9","author":"Faries","year":"2009","journal-title":"BMC Psychiatry"},{"key":"key20200910144218905_ref1-bib29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003546.pub2","article-title":"Management of sexual dysfunction due to antipsychotic drug therapy","volume":"1","author":"Berner","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"key20200910144218905_ref1-bib30","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/archpsyc.1991.01810320088015","article-title":"A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system","volume":"48","author":"McGuffin","year":"1991","journal-title":"Arch Gen Psychiatry"},{"key":"key20200910144218905_ref1-bib31","volume-title":"Sexual Health","author":"NHS Choices"},{"key":"key20200910144218905_ref1-bib32","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00213-002-1344-3","article-title":"Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study","volume":"166","author":"Casey","year":"2003","journal-title":"Psychopharmacology"},{"key":"key20200910144218905_ref1-bib33","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/clpt.2010.70","article-title":"Sexual side effects of pharmacological treatment of psychiatric diseases","volume":"89","author":"Serretti","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"key20200910144218905_ref1-bib34","unstructured":"National Institute for Health and Care Excellence (NICE). Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care. London: NICE; 2009."},{"key":"key20200910144218905_ref1-bib35","volume-title":"Antipsychotic Dosage Ready Reckoner\u2013Version 6.1","author":"Prescribing Observatory for Mental Health-UK"},{"key":"key20200910144218905_ref1-bib36","unstructured":"Joint Formulary Committee. British National Formulary. 74 ed. London: BMJ Group and Pharmaceutical Press; 2018."},{"key":"key20200910144218905_ref1-bib37","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(13)62366-1","article-title":"Sexual function in Britain: findings from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3)","volume":"382","author":"Mitchell","year":"2013","journal-title":"Lancet"},{"key":"key20200910144218905_ref1-bib38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3928\/0048-5713-19990101-10","article-title":"Assessment of sexual dysfunction using the Arizona Sexual Experiences Scale (ASEX) and the implications for the treatment of depression","volume":"29","author":"McGahuey","year":"1999","journal-title":"Psychiatr Ann"},{"key":"key20200910144218905_ref1-bib39","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1136\/sti.77.2.84","article-title":"Measuring sexual behaviour: methodological challenges in survey research","volume":"77","author":"Fenton","year":"2001","journal-title":"Sex Transm Infect"},{"key":"key20200910144218905_ref1-bib40","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1177\/0269881115593893","article-title":"Rating scales to measure side effects of antipsychotic medication: a systematic review","volume":"29","author":"van Strien","year":"2015","journal-title":"J Psychopharmacol"},{"key":"key20200910144218905_ref1-bib41","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.comppsych.2014.04.006","article-title":"Reliability and validity of the Arizona sexual experiences scale \u2013 Arabic version in Tunisian patients with schizophrenia","volume":"55","author":"Nakhli","year":"2014","journal-title":"Compr Psychiatry"},{"key":"key20200910144218905_ref1-bib42","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1590\/S0101-60832009000500002","article-title":"The accuracy of the Arizona Sexual Experience Scale (ASEX) to identify sexual dysfunction in patients of the schizophrenia spectrum","volume":"6","author":"Nunes","year":"2009","journal-title":"Rev Psiquiatr Clin"},{"key":"key20200910144218905_ref1-bib43","volume-title":"Assessment Manual for Psychopharmacology \u2013 Revised","author":"Guy","year":"1976"},{"key":"key20200910144218905_ref1-bib44","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"key20200910144218905_ref1-bib45","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1177\/0269881108091069","article-title":"Interrater reliability of the Antipsychotic Non-Neurological Side-Effects Rating Scale (ANNSERS)","volume":"22","author":"Ohlsen","year":"2008","journal-title":"Psychopharmacology"},{"key":"key20200910144218905_ref1-bib46","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.schres.2007.12.470","article-title":"The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder","volume":"100","author":"Byerly","year":"2008","journal-title":"Schizophr Res"},{"key":"key20200910144218905_ref1-bib47","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.drugalcdep.2005.05.015","article-title":"Cost-effectiveness of screening and referral to an alcohol health worker in alcohol misusing patients attending an accident and emergency department: a decision-making approach","volume":"81","author":"Barrett","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"key20200910144218905_ref1-bib48","volume-title":"Quality of Life and Pharmacoeconomics in Clinical Trials","author":"Kind","year":"1996","edition":"2nd"},{"key":"key20200910144218905_ref1-bib49","volume-title":"Development and Validation of the Recovering Quality of Life (ReQoL) Outcome Measures","author":"Keetharuth","year":"2017"},{"key":"key20200910144218905_ref1-bib50","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1002\/sim.4175","article-title":"Generalised method for adaptive randomisation in clinical trials","volume":"30","author":"Russell","year":"2011","journal-title":"Stat Med"},{"key":"key20200910144218905_ref1-bib51","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1440-1819.2010.02156.x","article-title":"Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: a case series","volume":"65","author":"Chen","year":"2011","journal-title":"Psychiatry Clin Neurosci"},{"key":"key20200910144218905_ref1-bib52","doi-asserted-by":"publisher","first-page":"e846","DOI":"10.1136\/bmj.e846","article-title":"Group art therapy as an adjunctive treatment for people with schizophrenia: multicentre pragmatic randomised trial","volume":"344","author":"Crawford","year":"2012","journal-title":"BMJ"},{"key":"key20200910144218905_ref1-bib53","doi-asserted-by":"publisher","first-page":"e74210","DOI":"10.1371\/journal.pone.0074210","article-title":"Randomised controlled trial of joint crisis plans to reduce compulsory treatment for people with psychosis: economic outcomes","volume":"8","author":"Barrett","year":"2013","journal-title":"PLOS ONE"},{"key":"key20200910144218905_ref1-bib54","volume-title":"Unit Costs of Health and Social Care 2018","author":"Curtis","year":"2019"},{"key":"key20200910144218905_ref1-bib55","volume-title":"Evaluation of NHS 111 Pilot Sites","author":"Turner","year":"2012"},{"key":"key20200910144218905_ref1-bib56","unstructured":"Department of Health and Social Care (DHSC). National Schedule of Reference Costs 2017\u201318. London: DHSC; 2018."},{"key":"key20200910144218905_ref1-bib57","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"key20200910144218905_ref1-bib58","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1192\/bjp.2017.10","article-title":"Recovering Quality of Life (ReQoL): a new generic self-reported outcome measure for use with people experiencing mental health difficulties","volume":"212","author":"Keetharuth","year":"2018","journal-title":"Br J Psychiatry"},{"key":"key20200910144218905_ref1-bib59","unstructured":"National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology Appraisal 2013. London: NICE; 2013."},{"key":"key20200910144218905_ref1-bib60","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1192\/bjp.bp.112.122283","article-title":"Using generic preference-based measures in mental health: psychometric validity of the EQ-5D and SF-6D","volume":"205","author":"Mulhern","year":"2014","journal-title":"Br J Psychiatry"},{"key":"key20200910144218905_ref1-bib61","doi-asserted-by":"publisher","first-page":"h1258","DOI":"10.1136\/bmj.h1258","article-title":"Process evaluation of complex interventions: Medical Research Council guidance","volume":"350","author":"Moore","year":"2015","journal-title":"BMJ"},{"key":"key20200910144218905_ref1-bib62","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"Braun","year":"2006","journal-title":"Qual Res Psychol"},{"key":"key20200910144218905_ref1-bib63","volume-title":"Schizophrenia Top 10","author":"James Lind Alliance"},{"key":"key20200910144218905_ref1-bib64","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"key20200910144218905_ref1-bib65","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/j.1365-2648.2010.05260.x","article-title":"Discussing sexuality with patients: nurses\u2019 attitudes and beliefs","volume":"66","author":"Saunam\u00e4ki","year":"2010","journal-title":"J Adv Nurs"},{"key":"key20200910144218905_ref1-bib66","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1046\/j.1351-0126.2001.00425.x","article-title":"An initial exploration of community mental health nurses\u2019 attitudes to and experience of sexuality-related issues in their work with people experiencing mental health problems","volume":"8","author":"Cort","year":"2001","journal-title":"J Psychiatr Ment Health Nurs"},{"key":"key20200910144218905_ref1-bib67","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/j.1447-0349.2010.00705.x","article-title":"Talking or avoiding? Mental health nurses\u2019 views about discussing sexual health with consumers","volume":"20","author":"Quinn","year":"2011","journal-title":"Int J Ment Health Nurs"},{"key":"key20200910144218905_ref1-bib68","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1348\/147608304322874236","article-title":"The quest for well-being: a qualitative study of the experience of taking antipsychotic medication","volume":"77","author":"Carrick","year":"2004","journal-title":"Psychol Psychother"},{"key":"key20200910144218905_ref1-bib69","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/j.1600-0447.2009.01356.x","article-title":"The subjective experience of taking antipsychotic medication: a content analysis of Internet data","volume":"120","author":"Moncrieff","year":"2009","journal-title":"Acta Psychiatr Scand"},{"key":"key20200910144218905_ref1-bib70","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/jpm.12288","article-title":"What is it like to take antipsychotic medication? A qualitative study of patients with first-episode psychosis","volume":"23","author":"Gray","year":"2016","journal-title":"J Psychiatr Ment Health Nurs"},{"key":"key20200910144218905_ref1-bib71","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12991-015-0066-y","article-title":"Pharmacy switch of antipsychotic medications: patient\u2019s perspective","volume":"14","author":"Murawiec","year":"2015","journal-title":"Ann Gen Psychiatry"},{"key":"key20200910144218905_ref1-bib72","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1176\/appi.ajp.2007.06071075","article-title":"Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial","volume":"164","author":"Shim","year":"2007","journal-title":"Am J Psychiatry"},{"key":"key20200910144218905_ref1-bib73","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2165\/11587810-000000000-00000","article-title":"Antipsychotic polypharmacy in schizophrenia: benefits and risks","volume":"25","author":"Barnes","year":"2011","journal-title":"CNS Drugs"},{"key":"key20200910144218905_ref1-bib74","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1176\/appi.ajp.163.3.494","article-title":"Sildenafil in the treatment of antipsychotic-induced erectile dysfunction: a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial","volume":"163","author":"Gopalakrishnan","year":"2006","journal-title":"Am J Psychiatry"},{"key":"key20200910144218905_ref1-bib75","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ijgo.2015.08.015","article-title":"Systematic review and meta-analysis of phosphodiesterase type 5 inhibitors for the treatment of female sexual dysfunction","volume":"133","author":"Gao","year":"2016","journal-title":"Int J Gynaecol Obstet"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2033867","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta24440\/hta24440.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2033867","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T15:36:41Z","timestamp":1692113801000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta24440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":75,"journal-issue":{"issue":"44","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["10.3310\/hta24440"],"URL":"https:\/\/doi.org\/10.3310\/hta24440","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"5-2018","name":"contractual_start_date","label":"Contractual start date","group":{"name":"article_history","label":"Article History"}},{"value":"1-2020","name":"editorial_review_begun","label":"Editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"5-2020","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}